Overview

Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Primary objective To evaluate the efficacy of Acarbose add-on therapy on glucose control in subjects with type 2 diabetes inadequately controlled with Metformin and Sitagliptin combination therapy. The effect of acarbose, an alpha glucosidase inhibitor as a third-line therapeutic medication in subject who are inadequately controlled with metformin and DPP4 inhibitor will be evaluated with multicenter, randomized, 24-week, double blinded, placebo-controlled study in Korea.
Phase:
Phase 4
Details
Lead Sponsor:
The Catholic University of Korea
Collaborator:
Bayer
Treatments:
Acarbose
Metformin
Sitagliptin Phosphate